Managing Director
and access,
Dr. Ellen Baron is a strategic thinker with a high-level corporate perspective and broad business environment experience – equally facile in biotech or pharma. She has extensive international pharma/biotech deal-making expertise and a strong record of closing licensing and strategic partnerships. Ellen is committed to the success of emerging growth companies, bringing more than 30 years of industry experience with proven deal execution and unique access to the people, resources, and markets vital for success. She has been involved in the raise of more than $150M of investment capital and has $2B in deals to her credit from her days in pharma and biotech. Dr. Baron currently is a Co-Founder and Director of OpthalmX, Inc., a start-up developer of non-invasive treatments for hard-to-treat ophthalmic conditions using exosomes, and served as a Director of Tetragenetics Inc., a Boston-based biotech pioneering antibodies to ion channels acquired by AbCellera. Before joining Outcome Capital, Dr. Baron was a Managing Director at Healthios Capital Markets, LLC, leading their firm’s biopharmaceutical practice. Before that, she spent 9 years as a Partner at Oxford Bioscience Partners, a Boston-based life science venture capital firm where she led numerous therapeutic and diagnostic investments within the $1 billion portfolio of 149 companies. Ellen previously served as Senior Vice President, Business Development at Human Genome Sciences, a publicly traded biopharmaceutical company where she was responsible for all business functions of the Company including corporate partnering, licensing, and investor interface. Ellen previously spent 20 years at Schering-Plough Corporation in both Research and Development and Business Development. She has over 30 years of operating and investment expertise across the spectrum of the pharmaceutical and biotechnology industries, with particular emphasis in oncology, neurology, and infectious disease. Ellen holds a Ph.D. in Microbiology from Georgetown University School of Medicine and a post-doctorate at the Public Health Research Institute in New York. She is a FINRA Registered Securities Representative holding Series 79 and 63 registration.
